Prevention of Venous Thromboembolism in Internal Medicine with Unfractionated or Low-molecular-weight Heparins: A Meta-analysis of Randomised Clinical Trials

Summary

Background

The prevention of venous thromboembolic disease is less studied in medical patients than in surgery.

Methods

We performed a meta-analysis of randomised trials studying prophylactic unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in internal medicine, excluding acute myocardial infarction or ischaemic stroke. Deepvein thrombosis (DVT) systematically detected at the end of the treatment period, clinical pulmonary embolism (PE), death and major bleeding were recorded.

Results

Seven trials comparing a prophylactic heparin treatment to a control (15,095 patients) were selected. A significant decrease in DVT and in clinical PE were observed with heparins as compared to control (risk reductions = 56% and 58% respectively, p <0.001 in both cases), without significant difference in the incidence of major bleedings or deaths. Nine trials comparing LMWH to UFH (4,669 patients) were also included. No significant effect was observed on either DVT, clinical PE or mortality. However LMWH reduced by 52% the risk of major haemorrhage (p = 0.049).

Conclusions

This meta-analysis, based on the pooling of data available for several heparins, shows that heparins are beneficial in the prevention of venous thromboembolism in internal medicine.

Keywords

Heparin - internal medicine - venous thromboembolism - prophylaxis - meta-analysis

• References

• 1 Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. J Royal Soc Med 1989; 82: 198-200.
• 2 Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ. Factors associated with an antemorten diagnosis of major pulmonary embolism. Am J Med 1982; 73: 822-6.
• 3 Anderson FA, Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg 1992; 16: 707-14.
• 4 Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992; 305: 567-74.
• 5 Anderson FA, Wheeler HB, Goldberg RJ. et al A population-based perspective of the hospital incidence and case-facility rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991; 151: 933-8.
• 6 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162-73.
• 7 Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-20.
• 8 Mismetti P, Laporte-Simitsidis S, Tardy B, Queneau P, Decousus H. Prophylaxis of post operative venous thrombosis and pulmonary embolism by oral anticoagulants: a meta-analysis. Clinical Trials Meta-Analysis 1993; 28: 227-40.
• 9 Nurmohamed MT, Rosendaal FR, Buller HR. et al Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a metaanalysis. Lancet 1992; 340: 152-6.
• 10 Counsell C, Sandercock P. The efficacy and safety of anticoagulant therapy in patients with acute presumed ischaemic stroke: a systematic review of the randomized trials comparing anticoagulants with control. In: Warlow C, Van Gijn J, Sandercock P. The Cochrane Database Library. Cochrane Collaboration; issue 1. Oxford: update Software 1997..
• 11 Collins R, MacMahon S, Flather M. et al Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br Med J 1996; 313: 652-9.
• 12 Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248-54.
• 13 Cucherat M, Boissel JP, Leizorovicz A, Haugh MC. EasyMA: a program for the meta-analysis of clinical trials. Comp Methods Prog Biomed 1997; 53: 187-90.
• 14 Belch JJ, Lowe GDO, Ward AG, Forbes CD, Prentice CRM. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26: 115-7.
• 15 Cade JF, Andrews JT, Stubbs AE. Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Aust N Z J Med 1982; 12: 501-4.
• 16 Dahan R, Houlbert D, Caulin C. et al Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double blind trial. Haemostasis 1986; 16: 159-64.
• 17 Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate S. et al Prevalence and prevention of deep venous thrombosis of the lower extremities in high risk pulmonary patients. Angiology 1988; 39: 503-13.
• 18 Bergmann JF, Caulin C. Heparin prophylaxis in bedridden patients. Lancet 1996; 348: 205-6.
• 19 Gärdlung B. for the Heparin Prophylaxis Group. Randomized, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996; 347: 1357-61.
• 20 Fraisse E, Holzapfel L, Coulaud JM. et al Efficacy and safety of calcium Nadroparin (Fraxiparine®) in the prevention of deep-vein thrombosis during acute phase of chronic obstructive pulmonary disease. Submitted for publication 1998. Data provided by Sanofi Winthrop..
• 21 Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96: 561-5.
• 22 Poniewierski M, Barthels M, Kuhn M, Poliwoda H. Effectiveness of low molecular weight heparin (Fragmin®) in the prevention of thromboembolism in internal medicine patients. A randomized double blind study. Med Klin 1988; 83: 241-5.
• 23 Aquino JP, Gambier A, Ducros J. Prevention of thromboembolic accidents in elderly subjects with Fraxiparine. In: Fraxiparine, 2nd international symposium. Recent pharmacological and clinical data. Bounameaux H, Samama MM, Ten Cate JW. Stuttgart, New York: Schattauer; 1990: 51-4.
• 24 Harenberg J, Kallenbach B, Martin U. et al Randomised controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990; 59: 639-50.
• 25 Forette B, Wolmark Y. Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance. Presse Med 1995; 24: 567-71.
• 26 Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine (HESIM) Group. Haemostasis 1996; 26: 127-39.
• 27 Manciet G, Vergnes C, Vaissié JJ, Boisseau MR. Étude de l’efficacité et de la tolérance de Fraxiparine® administrée au long cours chez le sujet âgé: étude randomisée en double insu (APTE). Bounameaux H, Samama MM, Ten Cate JW. Stuttgart, New York: Schattauer; 1990: 55-9.
• 28 Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in nonsurgical patients: epidemiologal data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). The PRIME Study Group. Haemostasis 1996; 26: 49-56.
• 29 Bergmann JF, Neuhart E. from the Enoxaparin in Medicine Study Group (EMSG). A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996; 76: 529-34.
• 30 Kleber FX, Witt C, Flosbach CW, Koppenhagen K, Vogel G. and the PRINCE study group. Study to compare the efficacy and safety of the LMWH Enoxaparin and standard heparin in the prevention of thromboembolic events in medical patients with cardiopulmonary diseases. Ann Hematol 1998; 76 (Suppl. 01) P261.
• 31 Cogo A, Bernardi E, Prandoni P. et al Acquired risk factors for deep vein thrombosis in symptomatic outpatients. Arch Intern Med 1994; 154: 164-8.